Mark S Cooper

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8671206/publications.pdf

Version: 2024-02-01

90 papers	6,507 citations	117625 34 h-index	64796 79 g-index
93 all docs	93 docs citations	93 times ranked	6806 citing authors

#	Article	IF	Citations
1	Corticosteroid Insufficiency in Acutely Ill Patients. New England Journal of Medicine, 2003, 348, 727-734.	27.0	1,349
2	11Î²-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response. Endocrine Reviews, 2004, 25, 831-866.	20.1	897
3	Diagnosis and management of hypocalcaemia. BMJ: British Medical Journal, 2008, 336, 1298-1302.	2.3	318
4	Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). Thorax, 2015, 70, 617-624.	5.6	258
5	Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Critical Care Medicine, 2017, 45, 2078-2088.	0.9	234
6	Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Medicine, 2017, 43, 1751-1763.	8.2	220
7	Modulation of 11Î²-Hydroxysteroid Dehydrogenase Isozymes by Proinflammatory Cytokines in Osteoblasts: An Autocrine Switch from Glucocorticoid Inactivation to Activation. Journal of Bone and Mineral Research, 2001, 16, 1037-1044.	2.8	211
8	Osteoblastic 11Î²-Hydroxysteroid Dehydrogenase Type 1 Activity Increases With Age and Glucocorticoid Exposure. Journal of Bone and Mineral Research, 2002, 17, 979-986.	2.8	181
9	Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes and Endocrinology,the, 2013, 1, 59-70.	11.4	168
10	Glucocorticoids and Bone: Consequences of Endogenous and Exogenous Excess and Replacement Therapy. Endocrine Reviews, 2018, 39, 519-548.	20.1	162
11	11Î²-Hydroxysteroid Dehydrogenase Type 1 and Its Role in the Hypothalamus-Pituitary-Adrenal Axis, Metabolic Syndrome, and Inflammation. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4645-4654.	3.6	153
12	11Î²-Hydroxysteroid Dehydrogenase 1: Translational and Therapeutic Aspects. Endocrine Reviews, 2013, 34, 525-555.	20.1	152
13	Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases. Nature Reviews Rheumatology, 2020, 16, 133-144.	8.0	139
14	The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney International, 2008, 74, 495-504.	5.2	137
15	Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Intensive Care Medicine, 2017, 43, 1781-1792.	8.2	132
16	Outcome of Cushing's Disease following Transsphenoidal Surgery in a Single Center over 20 Years. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1194-1201.	3.6	130
17	11Î²-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects. Journal of Clinical Investigation, 2013, 123, 3051-3060.	8.2	110
18	11Î²-Hydroxysteroid Dehydrogenase Type 1 Activity Predicts the Effects of Glucocorticoids on Bone. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3874-3877.	3.6	89

#	Article	IF	Citations
19	Prereceptor regulation of glucocorticoid action by 11Î²â€hydroxysteroid dehydrogenase: a novel determinant of cell proliferation. FASEB Journal, 2002, 16, 36-44.	0.5	84
20	Differential expression, function and response to inflammatory stimuli of 11beta-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation. Arthritis Research and Therapy, 2006, 8, R108.	3.5	79
21	Association between bone mineral density and Câ€reactive protein in a large populationâ€based sample. Arthritis and Rheumatism, 2012, 64, 2624-2631.	6.7	66
22	Sensitivity of bone to glucocorticoids. Clinical Science, 2004, 107, 111-123.	4.3	59
23	Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency. European Journal of Endocrinology, 2016, 174, 531-538.	3.7	54
24	Critical Illness-Related Corticosteroid Insufficiency (CIRCI): A Narrative Review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Critical Care Medicine, 2017, 45, 2089-2098.	0.9	53
25	Characterisation of fibroblast-like synoviocytes from a murine model of joint inflammation. Arthritis Research and Therapy, 2013, 15, R24.	3.5	52
26	11Î²-Hydroxysteroid Dehydrogenase Type 1 Regulation by Intracellular Glucose 6-Phosphate Provides Evidence for a Novel Link between Glucose Metabolism and Hypothalamo-Pituitary-Adrenal Axis Function. Journal of Biological Chemistry, 2007, 282, 27030-27036.	3.4	48
27	Circulating cortisone levels are associated with biochemical markers of bone formation and lumbar spine BMD: the Hertfordshire Cohort Study. Clinical Endocrinology, 2005, 62, 692-697.	2.4	47
28	The pituitaryâ€“adrenal axis and body composition. Pituitary, 2009, 12, 105-115.	2.9	47
29	Vitamin D to Prevent Lung Injury Following Esophagectomyâ€”A Randomized, Placebo-Controlled Trial*. Critical Care Medicine, 2018, 46, e1128-e1135.	0.9	45
30	Inflammatory regulation of glucocorticoid metabolism in mesenchymal stromal cells. Arthritis and Rheumatism, 2012, 64, 2404-2413.	6.7	43
31	Adrenal gland and bone. Archives of Biochemistry and Biophysics, 2010, 503, 137-145.	3.0	38
32	11Î²-Hydroxysteroid dehydrogenase type 1 within muscle protects against the adverse effects of local inflammation. Journal of Pathology, 2016, 240, 472-483.	4.5	38
33	The mesenchymal stem cell marker CD248 (endosialin) is a negative regulator of bone formation in mice. Arthritis and Rheumatism, 2012, 64, 3334-3343.	6.7	37
34	Endogenous Glucocorticoids and Bone. Bone Research, 2013, 1, 107-119.	11.4	37
35	Synovial DKK1 expression is regulated by local glucocorticoid metabolism in inflammatory arthritis. Arthritis Research and Therapy, 2012, 14, R226.	3.5	36
36	Comparison of blood sampling methods for plasma corticosterone measurements in mice associated with minimal stress-related artefacts. Steroids, 2018, 135, 69-72.	1.8	35

#	Article	IF	Citations
37	The 11Â-hydroxysteroid dehydrogenase enzymes--arbiters of the effects of glucocorticoids in synovium and bone. Rheumatology, 2010, 49, 2016-2023.	1.9	31
38	Glucocorticoids, bone and energy metabolism. Bone, 2016, 82, 64-68.	2.9	31
39	Vitamin D to prevent acute lung injury following oesophagectomy (VINDALOO): study protocol for a randomised placebo controlled trial. Trials, 2013, 14, 100.	1.6	30
40	Disruption of glucocorticoid signaling in chondrocytes delays metaphyseal fracture healing but does not affect normal cartilage and bone development. Bone, 2014, 69, 12-22.	2.9	27
41	Cumulative dispensing of high oral corticosteroid doses for treating asthma in Australia. Medical Journal of Australia, 2020, 213, 316-320.	1.7	26
42	Local steroid activation is a critical mediator of the anti-inflammatory actions of therapeutic glucocorticoids. Annals of the Rheumatic Diseases, 2021, 80, 250-260.	0.9	24
43	Glucocorticoid-Induced Osteoporosis ? A Disorder of Mesenchymal Stromal Cells?. Frontiers in Endocrinology, 2011, 2, 24.	3.5	22
44	Disorders of calcium metabolism and parathyroid disease. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 975-983.	4.7	21
45	DKK1 expression by synovial fibroblasts in very early rheumatoid arthritis associates with lymphocyte adhesion in an in vitro flow co-culture system. Arthritis Research and Therapy, 2016, 18, 14.	3.5	20
46	Endogenous glucocorticoids in inflammation: contributions of systemic and local responses. Swiss Medical Weekly, 2012, 142, w13650.	1.6	19
47	Selective glucocorticoid receptor agonists: Glucocorticoid therapy with no regrets?. Journal of Bone and Mineral Research, 2012, 27, 2238-2241.	2.8	18
48	Endogenous glucocorticoid signaling in chondrocytes attenuates joint inflammation and damage. FASEB Journal, 2018, 32, 478-487.	0.5	18
49	The response of T cells to interleukinâ€6 is differentially regulated by the microenvironment of the rheumatoid synovial fluid and tissue. Arthritis and Rheumatism, 2011, 63, 3284-3293.	6.7	17
50	TNFÎ± regulates cortisol metabolism in vivo in patients with inflammatory arthritis. Annals of the Rheumatic Diseases, 2015, 74, 464-469.	0.9	17
51	Diagnosis and Treatment of ACTH Deficiency. Reviews in Endocrine and Metabolic Disorders, 2005, 6, 47-54.	5.7	16
52	Successful Asfotase Alfa Treatment in an Adult Dialysis Patient With Childhood-Onset Hypophosphatasia. Journal of the Endocrine Society, 2017, 1, 1188-1193.	0.2	16
53	Can 11Î²-Hydroxysteroid Dehydrogenase Activity Predict the Sensitivity of Bone to Therapeutic Glucocorticoids in Inflammatory Bowel Disease?. Calcified Tissue International, 2011, 89, 246-251.	3.1	15
54	Glucocorticoids in bone and joint disease: the good, the bad and the uncertain. Clinical Medicine, 2012, 12, 261-265.	1.9	15

#	Article	IF	Citations
55	Ten false beliefs about cortisol in critically ill patients. Intensive Care Medicine, 2015, 41, 1817-1819.	8.2	15
56	Transgenic Disruption of Glucocorticoid Signaling in Osteoblasts Attenuates Joint Inflammation in Collagen Antibodyâ€“Induced Arthritis. American Journal of Pathology, 2016, 186, 1293-1301.	3.8	14
57	Expression of 11Î²-hydroxysteroid dehydrogenase enzymes in human osteosarcoma: potential role in pathogenesis and as targets for treatments. Endocrine-Related Cancer, 2012, 19, 589-598.	3.1	12
58	Targeting 11Î²-hydroxysteroid dehydrogenases: a novel approach to manipulating local glucocorticoid levels with implications for rheumatic disease. Current Opinion in Pharmacology, 2013, 13, 440-444.	3.5	12
59	Differential glucocorticoid metabolism in patients with persistent versus resolving inflammatory arthritis. Arthritis Research and Therapy, 2015, 17, 121.	3.5	12
60	Endogenous Glucocorticoid Metabolism in Bone: Friend or Foe. Frontiers in Endocrinology, 2021, 12, 733611.	3.5	11
61	Overview of the endocrine response to critical illness: How to measure it and when to treat. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 705-717.	4.7	10
62	Dihydrotestosterone (DHT) Enhances Wound Healing of Major Burn Injury by Accelerating Resolution of Inflammation in Mice. International Journal of Molecular Sciences, 2020, 21, 6231.	4.1	9
63	Global Deletion of 11Î²-HSD1 Prevents Muscle Wasting Associated with Glucocorticoid Therapy in Polyarthritis. International Journal of Molecular Sciences, 2021, 22, 7828.	4.1	9
64	Glucocorticoid metabolism in rheumatoid arthritis. Annals of the New York Academy of Sciences, 2014, 1318, 18-26.	3.8	8
65	Skeletal glucocorticoid signalling determines leptin resistance and obesity in aging mice. Molecular Metabolism, 2020, 42, 101098.	6.5	8
66	TNFÎ±-mediated Hsd11b1 binding of NF-ÎºB p65 is associated with suppression of 11Î²-HSD1 in muscle. Journal of Endocrinology, 2014, 220, 389-396.	2.6	7
67	Unravelling how glucocorticoids work in rheumatoid arthritis. Nature Reviews Rheumatology, 2018, 14, 566-567.	8.0	7
68	Review: New perspectives in the management of primary hyperparathyroidism. Therapeutic Advances in Endocrinology and Metabolism, 2010, 1, 197-205.	3.2	6
69	Glucocorticoid-induced osteoporosis. Current Opinion in Endocrinology, Diabetes and Obesity, 2001, 8, 140-145.	0.6	5
70	Role of 11Î²-HSD type 1 in abnormal HPA axis activity during immune-mediated arthritis. Endocrine Connections, 2018, 7, 385-394.	1.9	5
71	The contradictory role of androgens in cutaneous and major burn wound healing. Burns and Trauma, 2021, 9, tkaa046.	4.9	5
72	Effect of AZD4017, a Selective 11Î²-HSD1 Inhibitor, on Bone Turnover Markers in Postmenopausal Osteopenia. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2026-2035.	3.6	4

#	Article	IF	Citations
73	Bone protective therapy in the young patient with fractures and chronic disease: what drug(s) should be given and for how long?. Clinical Endocrinology, 2009, 70, 188-191.	2.4	3
74	Glucocorticoid-induced osteoporosis: how best to avoid fractures. Therapeutic Advances in Chronic Disease, 2010, 1, 17-23.	2.5	2
75	Controlled dual release of dihydrotestosterone and flutamide from polycaprolactone electrospun scaffolds accelerate burn wound healing. FASEB Journal, 2022, 36, e22310.	0.5	2
76	11Î²-Hydroxysteroid Dehydrogenase Type 1 within Osteoclasts Mediates the Bone Protective Properties of Therapeutic Corticosteroids in Chronic Inflammation. International Journal of Molecular Sciences, 2022, 23, 7334.	4.1	2
77	Is hydrocortisone an effective treatment for septic shock?. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 368-369.	2.8	1
78	Preface. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 703-704.	4.7	1
79	Diabetes Endocrinology in Medical Education (DEME) Survey - an evaluation of diabetes and endocrinology teaching at a UK medical school. British Journal of Diabetes and Vascular Disease, 2012, 12, 153-154.	0.6	1
80	Role of endocrine dysfunction in frequently unexplained disorders. European Journal of Pain, 2014, 18, 299-300.	2.8	1
81	Therapeutic patenting for glucocorticoid-induced osteoporosis. Expert Opinion on Therapeutic Patents, 2000, 10, 847-857.	5.0	0
82	Drug-induced bone disease. Adverse Drug Reaction Bulletin, 2005, &NA;, 903-906.	0.5	0
83	Effect of systemic glucocorticoid therapy on bone metabolism: an update. Expert Review of Endocrinology and Metabolism, 2006, 1, 111-122.	2.4	0
84	Our approach to osteoporosis screening and treatment needs to change. Cmaj, 2008, 178, 1683-1684.	2.0	0
85	Glucocorticoids in the critically ill. , 0, , 144-154.		0
86	Variation in 'normal' thyroid functionâ€"effect on bone health?. Nature Reviews Endocrinology, 2010, 6, 599-600.	9.6	0
87	Increased fracture risk in patients treated with thiazolidinediones: the role of abnormal bone turnover. Expert Review of Endocrinology and Metabolism, 2010, 5, 177-180.	2.4	0
88	A1.30â€...High 11Î²-HSD1 activity is associated with progression to rheumatoid arthritis in patients with early inflammatory arthritis. Annals of the Rheumatic Diseases, 2014, 73, A12.2-A13.	0.9	0
89	Demystifying adrenal dysfunction in severe illness. Clinical Endocrinology, 2019, 91, 372-373.	2.4	0
90	Basic and clinical aspects of glucocorticoid action in bone. , 2020, , 915-940.		0